[Obesity as a risk factor for atrial fibrillation]

Iwona Duraj1, Marlena Broncel1

  • 1Department of Internal Diseases and Clinical Pharmacology Medical University of Lodz.

Insights

Obesity is an independent risk factor for atrial fibrillation (AF), a growing public health concern. Research is exploring how obesity-related factors like inflammation and anatomical changes contribute to AF development.

Area of Science:

  • Cardiology and Public Health

Context:

  • Atrial fibrillation (AF) and obesity are significant global public health issues.
  • Obesity is an independent, modifiable risk factor for AF, with prevalence reaching epidemic proportions worldwide.
  • The link between obesity and AF is increasingly recognized, necessitating further investigation into underlying mechanisms.

Purpose:

  • To explore the mechanisms by which obesity predisposes individuals to atrial fibrillation.
  • To understand the role of inflammation and anatomical changes in obesity-induced AF.

Summary:

  • Obesity is a significant risk factor for atrial fibrillation (AF).
  • Potential mechanisms include altered atrial anatomy, increased atrial pressure, mechanical stretch, fibrosis, and disrupted electrical integrity.
  • Inflammation, particularly proinflammatory cytokines from epicardial adiposity, plays a crucial role.

Impact:

  • Highlights the critical need to address obesity as a modifiable risk factor for AF prevention and management.
  • Provides insights into the pathophysiology of AF in obese individuals.
  • Informs future research directions for targeted interventions.

Related Concept Videos

Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.5K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
335
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
368
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
279
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
577